FIRST-LINE GEFITINIB VS CARBOPLATIN/PACLITAXEL IN NON-SMALL CELL LUNG CANCER WITH EGFR MUTATION: PHASE III STUDY NEJ002

被引：0
|
作者：
Osamu, Ishimoto [1 ]
Kobayashi, Kunihiko [2 ]
Inoue, Akira [3 ]
Maemondo, Makoto
Sugawara, Shunichi [1 ]
Oizumi, Satoshi [4 ]
Saijo, Yasuo [5 ]
Gemma, Akihiko [6 ]
Morita, Satoshi [7 ]
Hagiwara, Koichi
Nukiwa, Toshihiro [3 ]
机构：
[1] Sendai Kosei Hosp, Sendai, Miyagi, Japan
[2] Saitama Med Univ, Int Med Ctr, Kawagoe, Saitama, Japan
[3] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[4] Hokkaido Univ, Sch Med, Sapporo, Hokkaido 060, Japan
[5] Hirosaki Univ, Sch Med, Hirosaki, Aomori, Japan
[6] Nippon Med Sch, Tokyo, Japan
[7] Yokohama City Univ, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
10.1093/annonc/mdq560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [31] Carboplatin plus Weekly Paclitaxel Combined with Bevacizumab as First-line Treatment for Non-small Cell Lung Cancer
    Yamasaki, Masahiro
    Murakami, Isao
    Nakano, Kikuo
    Doi, Mihoko
    Kitaguchi, Souichi
    Kondo, Tomohiro
    Sakurai, Joji
    Hattori, Noboru
    Arita, Ken-Ichi
    ANTICANCER RESEARCH, 2017, 37 (02) : 923 - 928
  • [32] Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)
    Shaw, Alice T.
    Ghizdavescu, Doru
    Jain, Minish
    Volovat, Constantin
    Subramaniam, Deepa
    Shuster, Dale
    Jin, Xiaoping
    Dutta, Dipen
    Pai, Seema
    von Roemeling, Reinhard
    CANCER RESEARCH, 2012, 72
  • [33] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Tsuji, F.
    Rosell, R.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Sbar, E.
    Wang, T.
    Zhang, H.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754
  • [34] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [35] Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    LUNG CANCER, 2011, 74 (03) : 469 - 473
  • [36] Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer
    Wu, Jenn-Yu
    Yu, Chong-Jen
    Shih, Jin-Yuan
    Yang, Chih-Hsin
    Yang, Pan-Chyr
    LUNG CANCER, 2010, 67 (03) : 348 - 354
  • [37] Phase Ib clinical study of first-line treatment with gefitinib in combination with bevacizumab and chemotherapy in advanced non-squamous non-small cell lung cancer with EGFR mutation.
    Xiong, Yanjuan
    Ren, Xiubao
    Liu, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany: An Observational Study
    Schuette, Wolfgang
    Schirmacher, Peter
    Eberhardt, Wilfried Ernst Erich
    Fischer, Juergen R.
    von der Schulenburg, J-Matthias Graf
    Mezger, Joerg
    Schumann, Christian
    Serke, Monika
    Zaun, Silke
    Dietel, Manfred
    Thomas, Michael
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (08) : 1254 - 1261
  • [39] Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel
    Arrieta, Oscar
    Anaya, Pablo
    Morales-Oyarvide, Vicente
    Alejandra Ramirez-Tirado, Laura
    Polanco, Ana C.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2016, 17 (07): : 855 - 863
  • [40] Analyses of Japanese patients recruited in IPASS, a phase III, randomized, open-label, first-line study of gefitinib vs carboplatin/paclitaxel in selected pts with advanced non-small-cell lung cancer
    Ichinose, Yukito
    Nishiwaki, Yutaka
    Ohe, Yuichiro
    Yamamoto, Nobuyuki
    Negoro, Shunichi
    Duffield, Emma
    Jiang Haiyi
    Saijo, Nagahiro
    Mok, Tony
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S443 - S443
12345